Biointaxis — Other · €2.17M

Biointaxis, a spin-off of the Germans Trias i Pujol Research Institute developing a gene therapy for Friedreich's ataxia that reaches both the central nervous system and peripheral organs including the heart, secured €2.17M in public funding — €1.7M from Spain's Ministry of Science, Innovation and Universities and €466,000 from a European Commission grant. This is grant/public money rather than an equity round; the company also had an equity crowdfunding campaign open on Capital Cell at the time.